ArticleJournal of computer-aided molecular design2026
Topological data analysis for antibody-drug conjugate payload discovery: a computational framework for mechanistic classification and target validation.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugate (ADC) payload discovery remains constrained by reliance on traditional molecular descriptors that inadequately capture three-dimensional geometric features governing target recognition and mechanism of action. Topological data analysis (TDA) offers a mathematical framework for characterizing molecular shape through persistent homology, potentially revealing mechanistic relationships invisible to conventional approaches. We developed a comprehensive TDA framework analyzing 22 FDA-approved ADC payloads across 1,471 clinical trial records, computing 31 topological descriptors encompassing Betti numbers, persistence statistics, and complexity metrics. Hierarchical clustering, principal component analysis, and correlation network analysis were employed for dimensionality reduction and cluster validation, with molecular docking studies validating TDA-derived classifications. TDA-based clustering identified eight distinct payload classes with excellent separation. Principal components captured 79.8% of topological variance, with Betti numbers and persistence lifetime as dominant features. Three major mechanistic clusters emerged: vinca alkaloids (tubulin inhibitors), camptothecins (topoisomerase I poisons), and DNA alkylators. Molecular docking demonstrated high performance within-cluster binding consistency and significant cross-cluster discrimination. We establish the first validated TDA framework for ADC payload discovery, demonstrating that persistent homology captures biologically meaningful mechanistic classifications suitable for rational payload design and mechanism-of-action prediction in precision oncology.
Indexed as
Identifiers
42397476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.